Compass Therapeutics, Inc. (CMPX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-05

Key Insights

Compass Therapeutics reported Q1 2026 financial results on May 5, 2026, with the detailed press release attached as Exhibit 99.1 but not disclosed in this filing summary.
The filing was signed by Neil Lerner, Chief Accounting Officer, indicating standard quarterly earnings disclosure procedures without executive leadership commentary.
As a NASDAQ-listed biopharmaceutical company, Compass Therapeutics maintains emerging growth company status but has not elected extended transition periods for accounting standards compliance.

Want the newest filings?

This analysis covers the filing from 2026-05-05. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-27

Tovecimig met its primary endpoint with a statistically significant 17.1% ORR vs 5.3% for paclitaxel alone (p=0.031) in second-line BTC, demonstrating meaningful clinical benefit and de-risking the Phase 2/3 program.
Progression-free survival showed strong results (4.7 months vs 2.6 months, HR=0.44, p<0.0001), but overall survival failed to meet the secondary endpoint due to 54% crossover from control arm, complicating the clinical picture and potentially affecting regulatory pathway.
Post-hoc analyses of crossover patients show tovecimig efficacy (median OS 12.8 months vs 6.1 months for non-crossover controls, p=0.04), suggesting the drug works but the trial design with high crossover limited OS assessment and may complicate approval discussions with FDA.
The company announced these results via press release and webcast on April 27, 2026, indicating confidence in data disclosure and proactive investor communication regarding both positive and challenging trial aspects.

Filed: 2026-03-05

Compass Therapeutics reported full-year 2025 financial results, indicating the company's operations and financial condition for the year.
The company did not provide any forward-looking guidance or commentary on its business performance and outlook.
There were no major announcements or disclosures of material events or agreements in this 8-K filing.

Filed: 2026-01-06

Compass Therapeutics reported unaudited preliminary cash, cash equivalents and marketable securities of approximately $209 million as of December 31, 2025, indicating a strong cash position to fund ongoing operations.
The company did not provide any updates on its product pipeline or business operations in the press release, limiting insights into its near-term growth prospects.
As an emerging growth company, Compass Therapeutics may have the flexibility to delay the adoption of new or revised financial accounting standards, which could impact the comparability of its future financial reporting.

Other reports for Compass Therapeutics, Inc.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.